256: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval
Andrew Joseph, STAT's Europe correspondent, joins us to explain the EU's sweeping proposal to overhaul how new drugs are regulated on the continent \u2014 and why the pharmaceutical industry is fighting it. We also discuss the latest news in the life sciences, including Lilly's surging business, a pair of new drug approvals, and a novel idea in Alzheimer's disease.